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ABSTRACT 
Osmotic drug delivery uses the osmotic pressure level for controlled delivery of drugs by using osmogens. Osmotic systems for  controlled drug-
delivery applications are well established, both in human pharmaceuticals and in veterinary medicine. The process of osmosis that can control 
the drug delivery system. Osmotic pressure created from external environment into the dosage form regulates the delivery of drug from 
osmotic device. Osmotic pumps are promising systems for controlled drug delivery. The systems are used for oral administration and 
implantation. Osmotic pumps consist of an inner core containing drug and coated with a semi permeable membrane. 
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INTRODUCTION 
Drug delivery System ;1-3 
Drug delivery is refer to the approaches, formulations, 
technologies, and systems for transporting the compound in 
the body as needed to safely achieve its desired therapeutic 
effect. It may be involve scientific site-targeting within the 
body or it might involve facilitating 
systemic pharmacokinetics in any case, it is typically 
concerned with both quantity and duration of drug presence. 
Drug delivery is often approached via a drug's chemical 
formulation, but it may also involve medical devices or drug-
device combination products. 
Drug delivery of the technologies modifies drug release profile 
absorption, distribution and elimination for the benefit of 
improving product efficacy and safety as well as patient 
convenience and compliance. Drug release is from diffusion, 
degradation, swelling, and affinity based mechanisms. 
Novel drug delivery system; 
 In the novel drug delivery systems (NDDS), there are various 
novel carriers which have advantage over conventional dosage 
forms. Conventional dosage forms show high dose and low 
availability, in-stability, first pass effect, plasma drug level 
fluctuations and rapid release of the drug. 
 Novel drug delivery system is one of the important tool of 
developed drug markets in pharmaceutical industry. Novel 
drug delivery system can minimize the problems by enhancing 
efficacy, safety, patient compliance and product shelf life.4 
Osmotic drug delivery System: 
Osmotic drug delivery system has come a long way since 
Australian physiologists Rose and Nelson developed an 
implantable pump in 1955. Osmotic drug delivery system used 
to  the osmotic pressure for controlled delivery of drugs by 
using osmogens (for up to 10 – 16 hrs). Osmotic systems for 
controlled drug-delivery applications are well established, 
both in human pharmaceuticals and in veterinary medicine.5 
oral drug delivery systems are known to provide the 
immediate release of drug, in which one cannot control the 
release of the drug and cannot maintain effective 
concentration at the target site for longer time.6few one 
compartment and two-compartment osmotic systems have 
been reviewed previously.7-10 
Osmotically controlled drug delivery system delivery the drug 
in a large extent and the delivery nature is independent of the 
physiological factors of the gastrointestinal tract and these 
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systems can be utilized for systemic as well as targeted 
delivery of drugs. Osmotically controlled oral drug delivery 
systems utilize osmotic pressure for controlled delivery of 
active agents.11 
 Osmotic Pump Controlled Release Preparation is a novel drug 
delivery system with permanently drug delivery rate as 
characteristic and controlled with the osmotic pressure 
difference between inside and outside of the semi permeable 
membrane as drug delivery power.12 
Osmosis can be defined as the spontaneous movement of a 
solvent from a solution of lower solute concentration to a 
solution of higher solute concentration through an ideal semi 
permeable membrane, which is permeable only to the solvent 
but should not permeable to the solute. The  pressure applied 
to the higher concentration side to inhibit solvent flow is 
called the osmotic pressure13. 
OSMOSIS: 
Process of movement of the solvent from the lower 
concentration of solution to the higher concentration of the 
solution through the semi permeable membrane. Osmosis is 
the process of control the drug delivery system. Osmotic 
pressure created due to imbibing of fluid from external 
environment into the dosage form regulates the delivery of 
drug from osmotic device. 
Rate of drug delivery from osmotic pump is directly 
proportional to the osmotic pressure developed due to 
imbibing of fluids by osmogen. Osmotic pressure is a 
colligative properties of   a solution in which the magnitude of 
osmotic pressure of the solution is independent on the 
number of discrete entities of solute present in the solution. 
Hence the release rate of drugs from osmotic distribute 
devices is dependent on the solubility and molecular weight 
and activity coefficient of the solute.14 
Principle of Osmosis; 
The first report of an osmotic effect dates to Abbenollet 
(1748). But Pfeffer obtained the first quantitative 
measurement in 1877. In the experiment a membrane 
permeable to water but impermeable to sugar is used to 
separate a sugar solution from pure water. A flow of water 
then takes place into the sugar solution that cannot be stop 
until a pressure π is applied to the sugar solution. Pfeffer 
showed that this pressure, the osmotic pressure π of the sugar 
solution is directly proportional to the solution concentration 
and the complete temperature. Within few years, Vant Hoff 
had shown the analogy between these results and ideal gas 
laws by the expression  
                                                        π = Ф c r t  
Where; 
 Ф = osmotic coefficient of the solution, 
 c = molar concentration of sugar in the solution, 
 r= gas constant,  
 t = absolute temperature.  
Osmotic pressure for concentrated solution of soluble solutes 
commonly used in controlled release formulation are 
extremely high ranging from 30 atm for sodium phosphate up 
to 500 atm  for a lactose-fructose mixture, as their osmotic 
pressure can produce high water flow across semi permeable 
membrane. The osmotic water flow through a membrane is 
given by the equation  
                                           Dv/dt = A Q Δ π/L  
Where 
 dv\dt =water flow across the membrane of area 
 A= thickness L, and the permeability  
Q in cm2 ,Δ π is the osmotic pressure difference between the 
two solutions on either side of the membrane.  
This equation is strictly for completely perm selective 
membrane that is membrane permeable to water but 
completely impermeable to osmotic agent.15 
Instrumentation 
Types of Osmotic Pumps; 
Osmotic pump; 
Osmotic pumps are most good systems for controlled drug 
delivery. These systems are used to oral 
administration. Osmotic pumps consist of an inner core 
containing drug coated with a semi permeable membrane. 
Rose-Nelson Pump; 
Rose and Nelson, the Australian scientists, were initiators of 
osmotic drug delivery. In 1955, they developed an implantable 
pump for the delivery of drugs to the sheep and cattle gut. 
 
Figure 1: Rose Nelson Pump. 
A semi-permeable membrane separate the salt from water 
chamber. The movement of water from the water chamber 
towards salt chamber is affcet by difference in osmotic 
pressure across the membrane. The volume of salt chamber 
increases due to water flow, which distends the latex 
diaphragm dividing the salt and drug chambers eventually, the 
drug is pumped out of the device. 
The kinetics of pumping from Rose Nelson pump is given by 
the following equation:  
dMt/ dt= (dV/ dt).C, 
where dMt/dt is the drug release rate, dV/dt is the volume 
flow of water into the salt chamber, and C represents the 
concentration of drug in the drug chamber. 
The major problem connect with Rose-Nelson pumps was that 
the osmotic action began whenever water came in contact 
with the semi permeable membrane. This needed pumps to be 
stored empty and water to be loaded prior to use. 
dMt/dt=AӨ∆π C/l 
where, A is the area of semi permeable membrane, Δπ is the 
osmotic pressure gradient, θ is the permeability of semi-
permeable membrane, and l is the thickness of semi-
permeable membrane. These basic equations are relevant to 
the osmotically driven controlled drug delivery devices. The 
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saturated salt solution created a high osmotic pressure 
compare to that pressure required for pumping the 
suspension of active agent. Therefore, the rate of water 
entering into the salt chamber remain constant as long as 
sufficient solid salt is present in die salt chamber to maintain a 
saturated solution and thereby a constant osmotic pressure 
driving force is generated. major problem associate with Rose-
Nelson pumps was that the osmotic action began whenever 
water came in contact with the semi-permeable membrane. 
This pumps to be stored empty and water to be loaded prior to 
use16. 
Higuchi-Leeper Osmotic Pump; 
 
Figure 2: Higuchi-Leeper osmotic pump 
This variation allows the device to be prepare loaded with 
drug and can be stored for long prior to use. Higuchi-Leeper 
pumps contain a rigid housing and a semi-permeable 
membrane supported on a perforated frame; a salt chamber 
containing a fluid solution with an excess of solid salt is 
usually present in this type of pump. Upon 
administration/implantation, surrounding biological fluid 
penetrates into the device through porous and semi-
permeable membrane and dissolves the MgSO4, creating 
osmotic pressure inside the device that pushes movable 
separator toward the drug chamber to remove drug outside 
the device. It is widely employed for the veterinary use. This 
type of pump is insert in body of an animal for delivery of 
antibiotics or growth hormones to animals.17 
Pulsatile delivery could be achieved by using Higuch- 
Leeper pump; 
The Pulsatile release of drug is achieved by drilling the orifice 
in elastic material that elastic under the osmotic pressure. 
Pulse release of drug is obtained after attained a certain 
critical pressure, which causes the orifice to open. The 
pressure then reduces to cause orifice closing and the cycle 
repeats to provide drug delivery in a pulsatile fashion. The 
orifice should be small enough to be substantially closed when 
the threshold level of osmotic pressure is not present.18 
 
Figure 3: Pulsatile release osmotic pump 
Higuchi-Theeuwes Osmotic Pump; 
In this device, the rigid housing consisted of a semi-permeable 
membrane. This membrane is strong enough to with stand the 
pumping pressure developed inside the device due to of water. 
The drug is loaded in the device only prior to its application, 
which extends advantage for storage of the device for longer 
duration. The release of the drug from the device is governed 
by the salt used in the salt chamber and the permeability 
characteristics of the outer membrane.19 
 
Figure 4: Higuchi Theeuwes Pump. 
Elementary Osmotic Pump (EOP); 
The Rose-Nelson pump was further simplified in the form of 
elementary osmotic pump which made osmotic delivery as a 
major method of achieve controlled drug release20-21. 
Elementary osmotic pump shown was invented by essentially 
contains an active agent having a suitable osmotic pressure; it 
is fabricated as a tablet coated with semi permeable 
membrane, usually cellulose acetate.22-23 
 
Figure 5: The elementary osmotic pump. 
 
 
 
The pump initially releases the drug at a rate given by the 
following equation; 
dMt/dt=(dV/dt).cs 
where  dV/dt depicts the water flow into the tablet and Cs is 
the solubility of the agent inside the tablet. 
Push-Pull Osmotic Pump (PPOP); 
Push-pull osmotic pump is delivered both poorly water 
soluble and highly water soluble drugs at a constant rate. This 
system resembles a standard bilayer coated tablet contains 
drug in a formulation of polymeric, osmotic agent, and other 
tablet excipients. This polymeric osmotic agent has the 
capacity to form a suspension of drug in situ. When this tablet 
later imbibes water, the other layer contains osmotic and 
colouring agents, polymer and tablet excipients. These layers 
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are formed and bonded together by tablet compression to 
form a single bilayer core. The tablet core is then coated with 
semi-permeable membrane. After the coating has been 
applied, a small hole is drilled through the membrane by a 
laser or mechanical drill on the drug layer side of the tablet.24-
25 
 
Figure 6: The push-pull osmotic pump (PPOP). 
Controlled Porosity Osmotic Pump (CPOP); 
Figure 6 represents the controlled porosity osmotic pump 
(CPOP). It is an osmotic tablet wherein the delivery orifices 
(holes) are formed in situ through leaching of water soluble 
pore-forming agents incorporated in semi-permeable 
membrane (SPM) (e.g., urea, nicotinamide, sorbitol, etc.). Drug 
release rate from CPOP depends on various factors like coating 
thickness, solubility of drug in tablet core, level of leachable 
pore-forming agent(s) and the osmotic pressure difference 
across the membrane26-27 
There are several obvious advantages inherent to the CPOP 
system. The stomach irritation problems are considerably 
reduced, as drug is released from the whole of the device 
surface rather from a single hole.27 
 
Figure 9: controlled porosity osmotic pump 
BASIC COMPONENTS OF OSMOTIC SYSTEMS 
Drug; 
Which have short biological half-life and which is used for 
prolonged treatment are ideal character for osmotic systems. 
Various drug candidates such as Diltiazem HCl, 
Carbamazepine, Metoprolol, Oxprenolol, etc are formulated as 
osmotic delivery. 
Semi-permeable membrane; 
An important part of the osmotic drug delivery system is the 
semi-permeable membrane housing. Therefore, the polymeric 
membrane selection is key to the osmotic delivery 
formulation. The membrane should possess certain 
characteristics, such as impermeability to the passage of drug 
and other ingredients present in the compartments. The 
membrane should be inert and maintain its dimensional 
integrity to provide a constant osmotic driving force during 
drug delivery.28 Any polymer that is permeable to water but 
impermeable to solute can be used as a coating material in 
osmotic devices. e.g. Cellulose esters like cellulose acetate, 
cellulose acetate butyrate, cellulose triacetate and ethyl 
cellulose and Eudragits.29 
Flux regulators; 
Delivery systems can be designed to regulate the permeability 
of the fluid by incorporating fluxregulating agents in the layer. 
Hydrophilic substances such as polyethethylene glycols (300 
to 6000 Da), polyhydric alcohols, polyalkylene glycols, and the 
like improve the flux, whereas hydrophobic materials such as 
phthalates substituted with an alkyl or alkoxy (e.g., diethyl 
phthalate or dimethoxy ethylphthalate) tend to decrease the 
flux. Insoluble salts or insoluble oxides, which are 
substantially water-impermeable materials, also can be used 
for this purpose.30 
Coating solvent; 
Solvents suitable for making polymeric solution that is used 
for manufacturing the wall of the osmotic device include inert 
inorganic and organic solvents that do not adversely harm the 
core, wall and other materials. The typical solvents include 
methylene chloride, acetone, methanol, ethanol, isopropyl 
alcohol, butyl alcohol, ethyl acetate, cyclohexane, carbon 
tetrachloride, water etc. The mixtures of solvents such as 
acetone-methanol (80:20), acetone-ethanol (80:20), acetone-
water (90:10), methylene chloride-methanol (79:21), 
methylene chloride-methanol-water (75:22:3) etc. can be 
used.31 
Wicking agent; 
A wicking agent is of either swellable or non-swellable nature. 
They are characterized by having the ability to undergo 
physiosorption with water. Physiosorption is a form of 
absorption in which the solvent molecules can loosely adhere 
to surface of the wicking agent via Van der waals interactions 
between the surface of the wicking agent and the absorbed 
molecule. The function of the wicking agent is to carry water 
to surfaces inside the core of the tablet there by creating 
channels or a network of increased surface area. Materials, 
which suitably for act as wicking agents include colloidal 
silicon dioxide, kaolin, titanium dioxide, alumina, niacinamide, 
sodium lauryl sulphate (SLS), low in weight poly (vinyl 
pyrolidone) PVP , m-pyrol, bentonite, magnesium aluminium 
silicate, polyester and polyethylene. SLS, colloidal silica and 
PVP are non swellable wicking agents.32 
Pore forming agent; 
The pore-forming agents cause the formation of micro porous 
membrane. The micro porous wall may be formed in situ by a 
pore-former by its leaching during the operation of the 
system. Thepore-formers can be inorganic or organic and solid 
or liquid in nature. For example, alkaline metal salts such as 
sodium chloride, sodium bromide, potassium chloride, 
potassium sulphate, potassium phosphate etc., alkaline earth 
metals such as calcium chloride and calcium nitrate, 
carbohydrates such as sucrose, glucose, fructose, mannose, 
lactose, sorbitol, and mannitol and, diols and polyols such as 
poly hydric alcohols, polyethylene glycols and polyvinyl 
pyrrolidone can be used as pore forming agents.33 
Plasticizers;34 
Different types and amount of plasticizers used in coating 
membrane also have a significant importance in the 
formulation of osmotic systems. They can change visco-elastic 
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behaviour of polymers and these changes may affect the 
permeability of the polymeric films. Some of the plasticizers 
used are as below. 
Polyethylene glycols 
Ethylene glycol monoacetate 
Diacetate- for low permeability 
Tri ethyl citrate 
Diethyl tartarate or Diacetin- for more permeable films 
Osmotic agent;35-37 
These are also known as osmogents and are used to create 
osmotic pressure inside the system. When the solubility of 
drug is low then the drug will show zero order release but at a 
slow rate. To enhance the release rate osmotic agent is added 
in the formulation. Osmotic agent creates a very high osmotic 
pressure gradient inside the system and increases release rate 
of drug. 
Some of the commercially used osmotic agents; 
Sodium chloride, Fructose, Sucrose, Potassium chloride, 
Xylitol, Sorbitol, Citric acid, Dextrose, 
Manitole and Lactose. 
Some Mixture Used As an Osmotic Agent; 
 Dextrose +Fructose 
 Lactose +Fructose36 
 Sucrose+ Fructose 
 Lactose +Dextrose 
 Mannitol +Fructose 
 Mannitol +Dextrose 
 Dextrose +Sucrose 
 Mannitol +Sucrose 
APPLICATION:38 
Osmotically controlled oral drug delivery system utilize 
osmotic pressure for controlled delivery of active agent. 
Alza corporation of USA was first to develop an oral osmotic 
pump,even today they are leaders in this field with a 
technology named OROSTM. 
Osmotic pumps have made tremendous progress and the 
available products based on this technology and number of 
patents granted in the last few years makes its presence felt in 
the market. 
Apart from drug delivery osmotic pumps can be used as 
experimental tools to determine important pharmacokinetic 
parameters of new existing drugs. 
Elementary osmotic pumps are suitable for delivery of drugs 
having moderate water solubility. 
Push-pull osmotic pumps can be used for delivery of drugs 
having extremes of water solubility 
ADVANTAGES39-43 
 The release rate of osmotic systems is highly predictable 
and can be programmed by modulating the release 
control parameters. 
 The delivery rate of zero-order is achievable with 
osmotic systems. 
 In the osmotic pump tablet frequency of dosing is 
reduced due to drug being released over a longer period 
of time unlike conventional tablets 
 The delivery rate of zero-order is achievable with 
osmotic systems. 
 Delivery may be delayed or pulsed, if desired. 
 Higher release rates are possible with osmotic systems 
compared with conventional diffusion-controlled drug 
delivery systems. 
 For oral osmotic systems, drug release is independent of 
gastric pH and hydrodynamic conditions. 
 The release from osmotic systems is minimally affected 
by the presence of food in gastrointestinal tract. 
 A high degree of in vivo- in vitro correlation (IVIVC) is 
obtained in osmotic systems. 
DISADVANTAGES; 
Release rate: The drug release rate can be altered by food and 
gastric transit time; as a result differences may arise in the 
release rate between doses. 
 Can not crush or chew products: Osmotic pump tablet should 
not be crushed or chewed as it can lead to loss of the ‘slow 
release’ characteristics as well as toxicity.44 
MARKETED PRODUCT45 
 Elementary Osmotic Pump 
Brand Name API 
Efidac 24 Chlorpheniramine 
Acutrim Phenylpropanolamine 
Sudafed 24 Pseudoephedrine 
Volmax Albuterol 
Minipress XL Prazocine 
 
Push-Pull Osmotic Systems 
Ditropan XL Oxybutynin chloride 
Procardia XL Nifedipine 
Glucotrol Glipizide 
Covera HS Verapamil HCl 
DynaCirc CR Isradipine 
Invega Paliperidone 
  
Implantable Osmotic Systems 
Viadur Leuprolide acetate 
Chronogesic Sufentanil 
 
CONCLUSION; 
 Osmotic drug delivery system are known to provide 
prolonged and controlled release of the drugs their by 
maintaining the effective concentration at the target site for 
longer duration.The osmotic delivery of drugs based on above 
review of the system.osmotic drugs delivery system is 
observed to provide a better delivery system of drugs 
intended for better therapeutic efficacy.   
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